Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Genomics|September 6, 2002
A single-nucleotide polymorphism of SMARCB1 in human breast cancersKoshi Mimori, Hiroshi Inoue, Takeshi Shiraishi, et al.
Oncology|July 26, 2002
Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assayKoshi Mimori, Ayumi Matsuyama, Keiji Yoshinaga, et al.
ACS Central Science|December 30, 2020
Rapid and Accurate Visualization of Breast Tumors with a Fluorescent Probe Targeting α-Mannosidase 2C1Kyohhei Fujita, Mako Kamiya, Takafusa Yoshioka, et al.
Oncology Reports|June 18, 2004
Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genesKoshi Mimori, Hiroaki Ueo, Tamotsu Kuroki, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2010
The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancerKenji Shibuta, Hiroaki Ueo, Hidemi Furusawa, et al.
Oncology Reports|August 4, 2005
Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancerHiroshi Inoue, Kenji Shibuta, Ayumi Matsuyama, et al.
The Journal of Clinical Investigation|January 3, 2015
F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous mannerKanae Yumimoto, Sayuri Akiyoshi, Hiroki Ueo, et al.
Breast Cancer Research : BCR|November 2, 2012
Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancerYoshimasa Kosaka, Akemi Kataoka, Hiroshi Yamaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 4, 2002
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]Rikiya Abe, Takeshi Tominaga, Tadashi Nomizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 4, 2002
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]Izo Kimijima, Takeshi Tominaga, Tadashi Nomizu, et al.
Pageof 3